BPC-157

BPC-157 is a 15-amino-acid sequence derived from a fragment of human gastric juice protein. Across rodent models it accelerates tendon-to-bone healing, ligament repair, and gut mucosal recovery — the candidate mechanisms include enhanced angiogenesis through the VEGFR2-eNOS-NO axis, increased fibroblast migration in tendon explants, and modulation of dopaminergic and serotonergic systems. The cross-system breadth of the rodent data is striking; the human data is far thinner.

BPC-157 is the peptide most people land on first. The mechanistic rodent literature is genuinely deep — tendon, ligament, GI, blood-brain barrier integrity — and reads like a candidate master-key for soft-tissue repair. The human evidence is almost entirely anecdotal, with a small handful of case reports and no published placebo-controlled RCTs at the time of this writing. Treat the rodent → human extrapolation with the appropriate skepticism, and read the source library for the actual study designs rather than the influencer summaries of them. Most user reports describe subcutaneous injection near the injury site (250–500 mcg, once or twice daily) for 4–8 weeks. Oral preparations exist but the published evidence on oral bioavailability is mixed. There is no consensus dose because there is no human RCT to calibrate one against.